The Abdera Therapeutics team (courtesy Abdera)

Ab­dera rais­es $110M to push tar­get­ed ra­dio­ther­a­pies where they haven’t gone be­fore

Ra­dio­phar­ma­ceu­ti­cal biotech Ab­dera has raised $110 mil­lion in a Se­ries B to get its first can­di­date in­to the clin­ic and build out its pipeline.

Ab­dera was born out of a part­ner­ship be­tween two Cana­di­an groups — an­ti­body biotech Ab­Cellera and life sci­ence ven­ture firm ad­Mare BioIn­no­va­tions. The groups came to­geth­er two years ago with an idea for a plat­form that could build tar­get­ing vec­tors specif­i­cal­ly for ra­dio­ther­a­pies. “The vast ma­jor­i­ty of the field up un­til re­cent­ly has re­al­ly been fo­cused on try­ing to sort of re­pur­pose an­ti­bod­ies that have al­ready been made in on­col­o­gy or oth­er tar­get­ing lig­ands,” co-founder and SVP of re­search Adam Judge told End­points News.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.